Markets:

Overview

News

Currencies

International

Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

165.34 +1.82 (+1.11%)

Streaming Delayed Price Updated: 3:36 PM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

August 14, 2025

Via Benzinga

Assessing Insmed: Insights From 20 Financial Analysts ↗

August 13, 2025

Via Benzinga

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗

August 13, 2025

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Via Stocktwits

Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

August 13, 2025

Via Benzinga

Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease ↗

August 12, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

What Does the Market Think About Insmed? ↗

June 19, 2025

Via Benzinga

How Do Investors Really Feel About Insmed? ↗

May 23, 2025

Via Benzinga

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic ↗

August 13, 2025

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

Via Stocktwits

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease ↗

August 12, 2025

The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients.

Via Benzinga

Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval ↗

August 12, 2025

Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition.

Via Investor's Business Daily

$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗

August 07, 2025

Via Benzinga

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 04, 2025

Via Investor Brand Network

Topics Government

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 04, 2025

EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗

July 24, 2025

Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.

Via Investor's Business Daily

Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' ↗

July 10, 2025

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for...

Via Benzinga

Topics Artificial Intelligence

A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts ↗

July 08, 2025

Via Benzinga

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

July 02, 2025

Via Benzinga

Russell Rebalance: 3 Stocks Ready to Move Higher

June 20, 2025

The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000

Via MarketBeat

Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? ↗

June 15, 2025

Top 10 large-cap stocks with biggest gains last week: INSM, CRCL, ORCL, ASTS, SAIL, VG, TEM, CASY, EQNR, HAL. Have you invested in them?

Via Benzinga

$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗

June 11, 2025

Via Benzinga

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast ↗

June 11, 2025

BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.

Via Benzinga

Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

June 11, 2025

Via Benzinga

Deep Dive Into Insmed Stock: Analyst Perspectives (6 Ratings) ↗

June 10, 2025

Via Benzinga

Dow Gains 50 Points; US Small Business Optimism Index Rises In May ↗

June 10, 2025

Via Benzinga

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

June 10, 2025

Via Benzinga

Which stocks are gapping on Tuesday? ↗

June 10, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday ↗

June 10, 2025

Via Benzinga

Insmed Stock Soars Pre-market After Lung Disease Drug Achieves Positive Results In Mid-Stage Trial: Retail Gets More Bullish ↗

June 10, 2025

Insmed said that it will immediately engage with the U.S. Food and Drug Administration (FDA) regarding a late-stage study design following the positive results from the mid-stage trial.

Via Stocktwits

Topics Death

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia ↗

June 10, 2025

Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.